Home / Business and Economy / Sanofi CEO Out: New Leader Takes Helm Amidst Board Shift
Sanofi CEO Out: New Leader Takes Helm Amidst Board Shift
12 Feb
Summary
- CEO Paul Hudson's mandate will not be renewed, ending February 17.
- Belén Garijo appointed as the new CEO, effective April 29.
- Olivier Charmeil to serve as Interim CEO during the transition period.
French pharmaceutical giant Sanofi announced a significant leadership transition. The Board of Directors has decided not to renew the mandate of current Chief Executive Officer Paul Hudson, whose final day of service is scheduled for February 17.
Belén Garijo has been appointed as the incoming Chief Executive Officer. Her tenure will officially commence at the close of the Group's Annual General Meeting on April 29. Shareholders are expected to vote on her appointment to the Board, which includes a proposal to amend the articles of association to accommodate her election.
During the interim period between Hudson's departure and Garijo's assumption of duties, Olivier Charmeil will serve as Interim Chief Executive Officer. Garijo brings extensive experience, having previously led Merck KGaA as CEO since 2021 and having been a long-standing member of Sanofi's Executive Committee for 15 years.


